Cytoreductive radical prostatectomy after chemohormonal therapy in patients with primary metastatic prostate cancer
Objective: Cytoreductive radical prostatectomy (cRP) has been proposed as local treatment option in metastatic hormone-sensitive prostate cancer (mHSPC) to prevent local complications and potentially improve oncological outcomes. In this study, we examined the feasibility of a multimodal concept wit...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-01-01
|
| Series: | Asian Journal of Urology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2214388221000266 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850043256680742912 |
|---|---|
| author | Christa Babst Thomas Amiel Tobias Maurer Sophie Knipper Lukas Lunger Robert Tauber Margitta Retz Kathleen Herkommer Matthias Eiber Gunhild von Amsberg Markus Graefen Juergen Gschwend Thomas Steuber Matthias Heck |
| author_facet | Christa Babst Thomas Amiel Tobias Maurer Sophie Knipper Lukas Lunger Robert Tauber Margitta Retz Kathleen Herkommer Matthias Eiber Gunhild von Amsberg Markus Graefen Juergen Gschwend Thomas Steuber Matthias Heck |
| author_sort | Christa Babst |
| collection | DOAJ |
| description | Objective: Cytoreductive radical prostatectomy (cRP) has been proposed as local treatment option in metastatic hormone-sensitive prostate cancer (mHSPC) to prevent local complications and potentially improve oncological outcomes. In this study, we examined the feasibility of a multimodal concept with primary chemohormonal therapy followed by cRP and analyzed prostate size reduction under systemic treatment, postoperative complication rates, as well as early postoperative continence. Methods: In this retrospective study, 38 patients with mHSPC underwent cRP after primary chemohormonal therapy (3-monthly luteinising hormone-releasing hormone-analogue + six cycles 3-weekly docetaxel 75 mg/m2) at two centers between September 2015 and December 2018. Results: Overall, 10 (26%) patients had high volume and 28 (74%) patients had low volume disease at diagnosis, according to CHAARTED definition. Median prostate-specific antigen (PSA) decreased from 65 ng/mL (interquartile range [IQR] 35.0–124.5 ng/mL) pre-chemotherapy to 1 ng/mL (IQR 0.3–1.7 ng/mL) post-chemotherapy. Prostate gland volume was significantly reduced by a median of 50% (IQR 29%–56%) under chemohormonal therapy (p = 0.003). Postoperative histopathology showed seminal vesicle invasion in 33 (87%) patients and negative surgical margins in 17 (45%) patients. Severe complications (Grade 3 according to Clavien-Dindo) were observed in 4 (11%) patients within 30 days. Continence was reached in 87% of patients after 1 month and in 92% of patients after 6 months. Median time to castration-resistance from begin of chemohormonal therapy was 41.1 months and from cRP was 35.9 months. Postoperative PSA-nadir ≤1 ng/mL versus >1 ng/mL was a significant predictor of time to castration-resistance after cRP (median not reached versus 5.3 months; p<0.0001). Conclusion: We observed a reduction of prostate volume under chemohormonal therapy going along with a low postoperative complication and high early continence rate. However, the oncologic benefit from cRP is still under evaluation. |
| format | Article |
| id | doaj-art-977dfb82a9bf40beb8784c23aa58c102 |
| institution | DOAJ |
| issn | 2214-3882 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Asian Journal of Urology |
| spelling | doaj-art-977dfb82a9bf40beb8784c23aa58c1022025-08-20T02:55:17ZengElsevierAsian Journal of Urology2214-38822022-01-0191697410.1016/j.ajur.2021.04.003Cytoreductive radical prostatectomy after chemohormonal therapy in patients with primary metastatic prostate cancerChrista Babst0Thomas Amiel1Tobias Maurer2Sophie Knipper3Lukas Lunger4Robert Tauber5Margitta Retz6Kathleen Herkommer7Matthias Eiber8Gunhild von Amsberg9Markus Graefen10Juergen Gschwend11Thomas Steuber12Matthias Heck13Department of Urology, Technical University of Munich, Rechts der Isar Medical Center, Munich, GermanyDepartment of Urology, Technical University of Munich, Rechts der Isar Medical Center, Munich, GermanyMartini-Klinik Prostate Cancer Center, Hamburg, GermanyMartini-Klinik Prostate Cancer Center, Hamburg, GermanyDepartment of Urology, Technical University of Munich, Rechts der Isar Medical Center, Munich, GermanyDepartment of Urology, Technical University of Munich, Rechts der Isar Medical Center, Munich, GermanyDepartment of Urology, Technical University of Munich, Rechts der Isar Medical Center, Munich, GermanyDepartment of Urology, Technical University of Munich, Rechts der Isar Medical Center, Munich, GermanyDepartment of Urology, Technical University of Munich, Rechts der Isar Medical Center, Munich, GermanyMartini-Klinik Prostate Cancer Center, Hamburg, GermanyMartini-Klinik Prostate Cancer Center, Hamburg, GermanyDepartment of Urology, Technical University of Munich, Rechts der Isar Medical Center, Munich, GermanyMartini-Klinik Prostate Cancer Center, Hamburg, GermanyDepartment of Urology, Technical University of Munich, Rechts der Isar Medical Center, Munich, Germany; Corresponding author.Objective: Cytoreductive radical prostatectomy (cRP) has been proposed as local treatment option in metastatic hormone-sensitive prostate cancer (mHSPC) to prevent local complications and potentially improve oncological outcomes. In this study, we examined the feasibility of a multimodal concept with primary chemohormonal therapy followed by cRP and analyzed prostate size reduction under systemic treatment, postoperative complication rates, as well as early postoperative continence. Methods: In this retrospective study, 38 patients with mHSPC underwent cRP after primary chemohormonal therapy (3-monthly luteinising hormone-releasing hormone-analogue + six cycles 3-weekly docetaxel 75 mg/m2) at two centers between September 2015 and December 2018. Results: Overall, 10 (26%) patients had high volume and 28 (74%) patients had low volume disease at diagnosis, according to CHAARTED definition. Median prostate-specific antigen (PSA) decreased from 65 ng/mL (interquartile range [IQR] 35.0–124.5 ng/mL) pre-chemotherapy to 1 ng/mL (IQR 0.3–1.7 ng/mL) post-chemotherapy. Prostate gland volume was significantly reduced by a median of 50% (IQR 29%–56%) under chemohormonal therapy (p = 0.003). Postoperative histopathology showed seminal vesicle invasion in 33 (87%) patients and negative surgical margins in 17 (45%) patients. Severe complications (Grade 3 according to Clavien-Dindo) were observed in 4 (11%) patients within 30 days. Continence was reached in 87% of patients after 1 month and in 92% of patients after 6 months. Median time to castration-resistance from begin of chemohormonal therapy was 41.1 months and from cRP was 35.9 months. Postoperative PSA-nadir ≤1 ng/mL versus >1 ng/mL was a significant predictor of time to castration-resistance after cRP (median not reached versus 5.3 months; p<0.0001). Conclusion: We observed a reduction of prostate volume under chemohormonal therapy going along with a low postoperative complication and high early continence rate. However, the oncologic benefit from cRP is still under evaluation.http://www.sciencedirect.com/science/article/pii/S2214388221000266Metastatic hormone-sensitive prostate cancerChemohormonal therapyCytoreductive radical prostatectomyFeasibilityPrevent local complicationsContinence rate |
| spellingShingle | Christa Babst Thomas Amiel Tobias Maurer Sophie Knipper Lukas Lunger Robert Tauber Margitta Retz Kathleen Herkommer Matthias Eiber Gunhild von Amsberg Markus Graefen Juergen Gschwend Thomas Steuber Matthias Heck Cytoreductive radical prostatectomy after chemohormonal therapy in patients with primary metastatic prostate cancer Asian Journal of Urology Metastatic hormone-sensitive prostate cancer Chemohormonal therapy Cytoreductive radical prostatectomy Feasibility Prevent local complications Continence rate |
| title | Cytoreductive radical prostatectomy after chemohormonal therapy in patients with primary metastatic prostate cancer |
| title_full | Cytoreductive radical prostatectomy after chemohormonal therapy in patients with primary metastatic prostate cancer |
| title_fullStr | Cytoreductive radical prostatectomy after chemohormonal therapy in patients with primary metastatic prostate cancer |
| title_full_unstemmed | Cytoreductive radical prostatectomy after chemohormonal therapy in patients with primary metastatic prostate cancer |
| title_short | Cytoreductive radical prostatectomy after chemohormonal therapy in patients with primary metastatic prostate cancer |
| title_sort | cytoreductive radical prostatectomy after chemohormonal therapy in patients with primary metastatic prostate cancer |
| topic | Metastatic hormone-sensitive prostate cancer Chemohormonal therapy Cytoreductive radical prostatectomy Feasibility Prevent local complications Continence rate |
| url | http://www.sciencedirect.com/science/article/pii/S2214388221000266 |
| work_keys_str_mv | AT christababst cytoreductiveradicalprostatectomyafterchemohormonaltherapyinpatientswithprimarymetastaticprostatecancer AT thomasamiel cytoreductiveradicalprostatectomyafterchemohormonaltherapyinpatientswithprimarymetastaticprostatecancer AT tobiasmaurer cytoreductiveradicalprostatectomyafterchemohormonaltherapyinpatientswithprimarymetastaticprostatecancer AT sophieknipper cytoreductiveradicalprostatectomyafterchemohormonaltherapyinpatientswithprimarymetastaticprostatecancer AT lukaslunger cytoreductiveradicalprostatectomyafterchemohormonaltherapyinpatientswithprimarymetastaticprostatecancer AT roberttauber cytoreductiveradicalprostatectomyafterchemohormonaltherapyinpatientswithprimarymetastaticprostatecancer AT margittaretz cytoreductiveradicalprostatectomyafterchemohormonaltherapyinpatientswithprimarymetastaticprostatecancer AT kathleenherkommer cytoreductiveradicalprostatectomyafterchemohormonaltherapyinpatientswithprimarymetastaticprostatecancer AT matthiaseiber cytoreductiveradicalprostatectomyafterchemohormonaltherapyinpatientswithprimarymetastaticprostatecancer AT gunhildvonamsberg cytoreductiveradicalprostatectomyafterchemohormonaltherapyinpatientswithprimarymetastaticprostatecancer AT markusgraefen cytoreductiveradicalprostatectomyafterchemohormonaltherapyinpatientswithprimarymetastaticprostatecancer AT juergengschwend cytoreductiveradicalprostatectomyafterchemohormonaltherapyinpatientswithprimarymetastaticprostatecancer AT thomassteuber cytoreductiveradicalprostatectomyafterchemohormonaltherapyinpatientswithprimarymetastaticprostatecancer AT matthiasheck cytoreductiveradicalprostatectomyafterchemohormonaltherapyinpatientswithprimarymetastaticprostatecancer |